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Background: Osteosarcoma (OS) affects over 8000 dogs/year in the United States. The disease usually arises in the
appendicular skeleton and metastasizes to the lung. Dogs with localized appendicular disease benefit from limb
amputation and chemotherapy but most die within 6–12 months despite these treatments. Taurolidine, a derivative
of taurine, has anti-tumor and anti-angiogenic effects against a variety of cancers. The following in vitro studies
tested taurolidine as a candidate for adjuvant therapy for canine OS. Tests for p53 protein status and caspase
activity were used to elucidate mechanisms of taurolidine-induced cell death.
Results: Taurolidine was cytotoxic to osteosarcoma cells and increased the toxicity of doxorubicin and carboplatin
in vitro. Apoptosis was greatly induced in cells exposed to 125 μM taurolidine and less so in cells exposed to
250 μM taurolidine. Taurolidine cytotoxicity appeared caspase-dependent in one cell line; with apparent mutant
p53 protein. This cell line was the most sensitive to single agent taurolidine treatment and had a
taurolidine-dependent reduction in accumulated p53 protein suggesting taurolidine’s effects may depend on the
functional status of p53 in canine OS.
Conclusion: Taurolidine’s cytotoxic effect appears dependent on cell specific factors which may be explained, in
part, by the functional status of p53. Taurolidine initiates apoptosis in canine OS cells and this occurs to a greater
extent at lower concentrations. Mechanisms of cell death induced by higher concentrations were not elucidated
here. Taurolidine combined with doxorubicin or carboplatin can increase the toxicity of these chemotherapy drugs
and warrants further investigation in dogs with osteosarcoma.
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Osteosarcoma (OS) is the most common cancer of bone
in dogs [1]. Tumors usually arise in the appendicular skel-
eton and metastasize to the lung. In cases with localized
appendicular disease, amputation of the affected limb
along with chemotherapy can extend life expectancy up to
about 12 months on average but there is no cure. An
increased understanding of the pathogenesis of OS is
needed in order to facilitate the development of more
effective therapeutic strategies. One such strategy is to* Correspondence: bernard.seguin@colostate.edu
1Department of Clinical Sciences, Oregon State University, Corvallis, USA
5Department of Clinical Sciences, Colorado State University, Fort Collins,
Colorado 80523, USA
Full list of author information is available at the end of the article
© 2013 Marley et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcombine drugs with different mechanisms of action in an
attempt to overcome tumor heterogeneity and drug resis-
tance. In this regard, it is reasonable to consider adding
new antineoplastic drugs to the treatments of patients
receiving traditional chemotherapeutics and one such can-
didate for this is the antimicrobial and antineoplastic drug
taurolidine [2,3].
Taurolidine is a derivative of the amino acid taurine
that has anti-tumor and anti-angiogenic effects against a
variety of cancers [4-6]. Originally developed for its anti-
bacterial properties, taurolidine has few detrimental
effects on normal cells [7] but inhibits cancer cell prolif-
eration [8] and tumor growth by inducing apoptosis
[5,9-12] possibly through p53-dependent mechanismsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Bax concentrations [9], and exerts anti-metastatic effects
within the tumor microenvironment through inhibition of
angiogenesis and endothelial cell adhesion [14]. Taurolidine
appears to induce autophagy and necroptosis in glioma
cell lines [15] and has been used to treat glioblastoma and
gastric carcinoma in humans [16,17]. This study tested
taurolidine against human and canine osteosarcoma cell
lines to determine its cytotoxicity and potential as an adju-




Four canine and one human OS cell lines were used in
this study. They included canine D17 (ATCC CCL183),
Clone 4, developed in our laboratory [18], COS [19], and
HMPOS [20], and the human cell line SAOS-2 (ATCC
HTB-85) which was included to establish consistency
with reports using human cell lines. Cells were cultured
at 37°C in a humidified 5% CO2 atmosphere in RPMI
1640 (Invitrogen) supplemented with 2mM glutamine,
2mM sodium pyruvate, 2mM HEPES, 1% pen-strep, and
10% fetal bovine serum. Taurolidine (2%) with and with-
out 5% polyvinylpyrrolidone (PVP) was kindly provided
by TauroPharm GmbH (Waldbüttelbrunn, Germany).
Doxorubicin (2mg/ml) and carboplatin (10 mg/ml)
were individually diluted 1:200 in RPMI 1640 prior to
use. Combinations of taurolidine with doxorubicin or
carboplatin were tested against SAOS-2, Clone 4, and
D17 cell lines.
Cell viability was assessed using an MTS assay (Promega).
Cells were seeded in 96-well plates at a density of 2500 or
5000 cells per well and allowed to adhere overnight. The
medium was then replaced with fresh medium containing
various concentrations of taurolidine, and/or doxorubicin
or carboplatin. Absorbance was measured at λ490 after 60
minutes, 37°C, incubation with the MTS product. Data are
expressed as means ± SD of triplicate wells, or quadrupli-
cate wells, for the carboplatin experiments and are repre-
sentative of at least two independent experiments.
The major effects of taurolidine were observed after 24
hrs incubation; therefore taurolidine-only experiments were
performed using a 24 hr incubation period and 5000 cells/
well in the 96-well plates. The doxorubicin and carboplatin
experiments required 72 hr incubation periods so these
were seeded with fewer cells (2500) to limit cell contact
inhibition.
Our initial experiments used taurolidine that contained
5% PVP which is used as a stabilizing agent for storage
purposes. Once we learned that dogs are allergic to PVP,
we changed to taurolidine without PVP. Thus taurolidine
without PVP was used for all subsequent experiments,
which were those that included carboplatin.Apoptotic changes in target cells were detected using
three independent methods. These included a colorimetric
ELISA based on the detection of nucleosomes formed as a
result of DNA fragmentation, flow cytometric detection of
early apoptotic changes in the cell membrane, and by
Western blot for PARP cleavage, which is an indirect indi-
cation of caspase activity. For the nucleosome ELISAs,
cells were initially treated as described above. After 12,
and 24 hrs exposure to 125 μM, 250 μM taurolidine or
PVP alone, culture supernatants were removed and pro-
cessed using a commercially available kit (Roche). Absor-
bance was measured at λ405.
Flow cytometry was used to detect binding of annexin-V
to phosphotidyl serine on the surface of cells in early apo-
ptosis and propidium iodide to DNA in late stage apoptosis
or dead cells. Tumor cells were incubated with 125 μM
taurolidine and collected, using 0.005% trypsin in PBS to
release the adherent cells, after 4, 24, and 48 hrs and
reacted with biotinylated annexin V-FITC and propidium
iodide using a commercially available kit (Calbiochem). A
minimum of 20,000 cells per sample were collected on a
Beckman Coulter FC-500 flow cytometer. Data analysis
and software compensation were performed using WinList
(Verity Software, Topsham, ME).
PARP cleavage, a surrogate marker of caspase activity,
was determined by Western blot using cells that had
been exposed to two concentrations of taurolidine with
and without prior incubation with the general caspase
inhibitor Z-VAD-FMK (CalBiochem ), as described [10].
Briefly, cells were seeded in 6-well plates (3 × 106/well)
and allowed to adhere overnight. Cells were incubated in
25 μM Z-VAD-FMK or DMSO in supplemented RPMI
medium for 60 min. The medium was changed and the
cells were subsequently incubated in 0, 125 or 250 μM
taurolidine in supplemented RPMI for 12 hrs and pro-
cessed as described below.
Cells were seeded (3 × 106/well) in 6-well plates and
allowed to adhere overnight prior to incubation as
described above and in figure legends. At the end of the
incubation period, the media and cells were removed,
using a cell scraper, and the cells were pelleted in a
tabletop centrifuge (3 min, 1200 × g). Cell pellets were
rinsed by re-suspending twice in 3 mls ice cold PBS and
extracted in 50 μl ice cold RIPA buffer with protease
inhibitor cocktail (Sigma). Extracts were sonicated four
times (1 sec each) using an ultrasonic dismembranator
(Fisher, Model 150T) and pelleted at 10,000 × g to re-
move cellular debris. Protein concentration was measured
using a Bradford assay (Bio-Rad). Proteins (20 μg/lane)
were separated on 4-12% SDS polyacrylamide gels and
transferred to PVDF membranes using standard methods.
The membranes were blocked in 1.5% albumin and
reacted with indicated primary antibodies diluted 1:200
for 3 hrs at room temperature (antibodies from Santa
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actin, sc-47778). The membranes were washed, reacted
with horseradish peroxidase-linked secondary antibody
(Santa Cruz Biotechnology, sc-2005) diluted 20,000:1, and
exposed to substrate (Thermo Scientific).
Because D17 cells expressed minimal amount of PARP,
we performed an immunoprecipitation (IP) prior to
Western blots as described above. Briefly, 100 μg PARP
antibody was suspended in 1 ml of IP buffer (25 mM
Tris, 150 mM NaCl; pH 7.2) and reacted overnight with
protein A/G linked agarose beads (Thermo Scientific).
The following day, 1 mg of protein from whole cell extracts
was added and allowed to react at room temperature
for 2 hours. The beads were rinsed several times in IP
buffer and immune complexes were eluted in 50 ul SDS
PAGE loading buffer and separated as described above for
Western blots.
Nuclear accumulation of p53 protein is an indication of
mutation in the p53 gene [21,22]. As an initial screen for
possible p53 mutants, we used immunocytochemistry to
detect abnormal expression of p53 in four canine OS cell
lines. Normal canine lymphocytes obtained from a fine
needle aspirate of a lymph node from a healthy dog were
used as a control. Cells were pelleted onto positively
charged slides and allowed to air dry. The slides were sub-
sequently fixed in acetone, air dried and stained according
to standard methods [23] using a monoclonal antibody
against p53 protein (sc-136023), chromagen Nova Red
(Vector Laboratories) as a secondary and hematoxylin
(Dako S3309) as the counter stain. Stained cells were
imaged on a microscope and scoring was performed
analogous to the Hercep Test system [24]. Briefly, two
independent individuals scored the staining intensity of
each slide in several representative fields using a subjective
scoring criteria consisting of a rating of 0 for no staining


























Figure 1 Effects of taurolidine or doxorubicin on proliferation of OS c
with doxorubicin B) and cytotoxic effects were determined using an MTS a
bars are too small to be visible.Phase contrast photomicrographs were obtained with
an inverted microscope (Eclipse ti, Nikon, Melville, NY)
using the 40X objective lens, and a digital camera.
Images were processed using NIS-Elements software
(Nikon, Melville, NY).
Data analyses
The 50% inhibitory concentrations (IC50s) were calcu-
lated with Prism Graphpad software using non-linear
regression and the log of the inhibitor versus variable
slope response equation. Constraints were set at 100%
for the top and 0 and −0.5 for the baselines in Figures 1
and 2 respectively.
The type of interaction between taurolidine and doxo-
rubicin or carboplatin was determined using the follow-
ing equations [25]:
Synergistic ¼ SFtþy < SFtxSFy
Additive ¼ SFtþy ¼ SFtxSFy
Sub additive ¼ SFtx SFy < SFtþy < SFtandSFy
Antagonistic ¼ SFtþy > SFtorSFy
SFt+y = surviving fraction of cells exposed to the com-
bination of taurolidine and doxorubicin or carboplatin,
SFt = surviving fraction of cells exposed to taurolidine
alone, SFy = surviving fraction of cells exposed to doxo-
rubicin or carboplatin alone. Interactions were determined
only for those combinations which led to a surviving frac-
tion of cells that were significantly different than those of
each individual drug at the same respective concentration.
These equations are appropriate provided the effect is
anti-proliferative [26], a condition that was met when the
interaction was determined except in cell line D17. At low
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Figure 2 Effects of doxorubicin or carboplatin ± taurolidine on proliferation of OS cell lines. Three OS cell lines were incubated for 72 hrs
in increasing concentrations of doxorubicin A) or carboplatin B) in the presence or absence of taurolidine and cytotoxic effects were evaluated
using an MTS assay. T0 indicates no taurolidine while T20 and T100 indicate 20 μM and 100 μM taurolidine respectively. Error bars indicate SD of
4 replicate wells. In some cases error bars are too small to be visible. * indicates a synergistic interaction (see methods). Data are presented as
percent difference from time 0 on the y-axis (see methods and results). Photomicrographs of D17 cells after 6 hr incubation with 100 nM
doxorubicin C) or with 100 nM doxorubicin plus 20 μM taurolidine. D) Cytoplasmic contraction is readily appreciated in the cells exposed to the
drug combination and represents an early apoptotic effect.
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tions, the SF of the control group was used in the equation
for the SF of carboplatin as it was the most stringent con-
ditions to evaluate the drug interaction.
Univariate ANOVA with Tukey’s posthoc tests, when
appropriate, were performed using PASW-17 software.Data in Figure 2A and 2B are normalized to a baseline
absorbance value taken at the initiation of the drug incu-
bation period, to account for the cell count at time zero,
and expressed as percent difference on the y-axis.
Flow cytometry data (Figure 3A) were analyzed using
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Figure 3 Mechanisms of taurolidine-induced cytotoxicity are cell line and concentration dependent. Binding of annexin-V-biotin-FITC and
propidium iodide (PI) to taurolidine-treated D17 OS cells was determined by 2-color flow cytometry. A) Data are displayed as dot plots and data
points in the lower right quadrant (i.e., annexin-V positive) represent early apoptotic cells while data points in the upper left quadrant represent
necrotic cells and points in the upper right quadrant (dual annexin-V/PI positive) represent cells in late apoptosis and necrosis. B) The release of
nucleosomes as an indicator of apoptosis following taurolidine treatment of D17 OS cells was determined at two time points. Data are expressed
as percent of apoptosis values measured in untreated cells at the same time points. The higher taurolidine concentration (250 μM) was less
effective at inducing apoptotic changes in this assay indicating cell death occurred by other mechanisms. T125, T250 = 125 μM and 250 μM
taurolidine respectively. * indicates different from 125 μM at same time point (p < .01). Error bars indicate SD. C) Western blots show degradation
of PARP as an indirect indicator of taurolidine-activated caspase activity in COS and HMPOS cells. Cells incubated 12 hrs in taurolidine as
described in methods. No loading control was available for the D17 blot because it was an immunoprecipitation. D) These proliferation assays
show the caspase inhibitor (CI) Z-VAD-FMK protects HMPOS but not D17 OSA cells from caspase-dependent cell death at low concentrations of
taurolidine, consistent with PARP cleavage seen in 3C. * indicates intercept is different between treated and untreated conditions (P < .05).
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Table 1 IC50s for human and canine osteosarcoma cell
lines treated with taurolidine or doxorubicin (inhibition
curves shown in Figure 1)






NR = IC50 Not Reached.
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lyzed using linear regression with Prism GraphPad, soft-




The potential effects of PVP alone were assessed by
comparing untreated cells with cells treated with PVP at
the same concentration as those in the high taurolidine
condition. This amounted to 0.07% PVP which had no
discernible effect on the cell lines or the MTS assay (data
not shown). Taurolidine had concentration-dependent
cytotoxic effects against all cell lines tested (Figure 1A).
The intensity of the cytotoxic effects of doxorubicin were
also cell line dependent with the major effects of the drug
occurring at the lower concentrations and little additional
benefit from higher concentrations of drug (Figure 1B).
The IC50s for taurolidine and doxorubicin alone are
shown in Table 1. Figure 2 shows the cytotoxic effects of
doxorubicin or carboplatin alone and in combination with
taurolidine. Data in Figure 2A and B are graphed using
percent difference along the y-axis. Thus, cells that have
doubled in number have a y value of 100. Zero indicates
no change in cell number and values below 0 indicate
cell numbers were lower than they were at the begin-
ning of the experiment. Graphed in this way, it can be
seen that 20 μM taurolidine enhanced the effect of
doxorubicin but the best that could be expected under
these conditions would be, on average, zero growth.
Adding 20 μM taurolidine to carboplatin enhanced the
effect of carboplatin alone but only in the D17 cell line.
In most cases, the 100 μM taurolidine plus carboplatinTable 2 IC50s for human and canine osteosarcoma cell lines t
(inhibition curves shown in Figure 2A and 2B)
Cell line Doxorubicin
(nM)




Saos-2 252 22 198
D17 100 12 414
Clone-4 NR 4 538
NR = IC50 Not Reached.combinations resulted in fewer remaining cells than
were present at time zero (y-axis values < 0). The IC50s
for the drug combination studies are shown in Table 2.
The photomicrographs in Figure 2C and D show doxo-
rubicin and doxorubicin plus taurolidine treated D17
cells (respectively) after 6 hours drug incubation. Only
the doxorubicin-taurolidine combination induced cyto-
plasmic contraction which is an early indicator of apo-
ptosis [23].
Taurolidine-induced apoptosis
Annexin V-FITC and propidium iodide flow cytometry
was used to quantify the proportion of D17 cells under-
going apoptosis and necrosis in response to 125 μM
taurolidine at three time points (Figure 3A). Apoptotic
changes predominated over necrosis during the early
stages of taurolidine cytotoxicity (p < .01). After 48
hours, 15% of D17 cells demonstrated early apoptotic
changes and 28% had progressed to late apoptotic or
necrotic stages (Figure 3A). The release of nucleosomes
from D17 cells was also used to evaluate the apoptotic
response to 125 μM and 250 μM taurolidine (Figure 3B).
The lower concentration of taurolidine triggered a greater
apoptotic response at both the 12 and 24 hour time points
(p < .05). The 125 μM concentration was also more effect-
ive at inducing caspase activity as indicated by PARP
cleavage (Figure 3C). The HMPOS cells showed the great-
est response with complete PARP cleavage when exposed
to 125 μM taurolidine. PARP cleavage was not observed
in HMPOS cells exposed to 250 μM taurolidine (data not
shown). The addition of caspase inhibitor (Z-VAD-FMK)
blocked PARP cleavage under these conditions indicating
that 125 μM taurolidine induces apoptosis by activating
the mitochondrial cytochrome-c caspase cascade [27].
This response was present but considerably less pro-
nounced in COS and SAOS-2 cells and was not seen in
the D17 and Clone 4 cell lines. Because taurolidine
induced PARP cleavage in the HMPOS but not D17 cells,
we investigated taurolidine-induced cytotoxicity with and
without caspase inhibition using an MTS cytotoxicity
assay. Figure 3D shows the caspase inhibitor had no effect
on the cytotoxic effect of taurolidine on D17 cells but
protected HMPOS cells from death in the presence of
low concentrations of taurolidine. These results indicate
that taurolidine exerts cytotoxic effects through multiplereated with doxorubicin or carboplatin ± taurolidine
in Carboplatin (μM) + 20 μM
Taurolidine





Figure 4 p53 protein accumulation in untreated osteosarcoma cells. Representative photomicrographs of cells probed with an antibody
against p53 protein show strong accumulation in HMPOS cells, moderate staining in Clone-4 and none in the D17 and COS cell lines. The signal
that can be observed in D17 and COS cells is the counterstain hematoxylin (see methods).
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pendent. We hypothesized these differences might be
modulated by the mutational/functional status of p53.
Taurolidine effects on expression of p53 protein in OS
cell lines
Because mutant p53 is responsible for evasion of apo-
ptosis in many cancers [28], we sought to determine the
role of p53-triggered apoptosis in response to taurolidine
treatment. First, immunocytochemistry was used to
evaluate canine OS cell lines for p53 expression in rest-
ing cells. Data shown in Figure 4, and summarized in
Table 3, suggest p53 protein accumulates strongly in
HMPOS, mildly in Clone-4 and is absent in COS and
D17 cells. Taurolidine treatment caused a dramatic
decrease in p53 protein expression in HMPOS but an
opposite effect in D17 cells where protein expression
strongly increased (Figure 5). We interpret this to indi-
cate the possibility that p53-mediated apoptosis in re-
sponse to taurolidine proceeds appropriately in D17, but
not in HMPOS cells [22,28].Table 3 Immunocytochemistry scores for p53 protein
accumulation. 0 indicates no detection and +++ indicates






Osteosarcoma continues to be a major cause of death
for dogs worldwide. Often, microscopic metastases exist
at diagnosis and these lead to a dismal prognosis. Early
treatment with chemotherapy and surgery prolongs sur-
vival but unacceptable drug toxicity prevents dose esca-
lation to levels capable of reversing metastatic disease.
New drug treatments are therefore desperately needed.
In the present studies we investigated taurolidine alone,
and in combination with doxorubicin or carboplatin
in vitro as a potential adjuvant therapy for canine OS.
The IC50s reported here are similar to those reported
for human OS cell lines [10] and a maximal apoptotic
response was observed at a concentration of 125 μM,
which is a clinically achievable concentration in bothFigure 5 Effects of taurolidine on p53 protein expression.
Western blots showing the effects of taurolidine exposure on this
cell cycle regulatory protein is concentration and cell line
dependent. The taurolidine-induced appearance of p53 protein in
D17 cells suggests these cells proceed through a p53-induced
apoptotic pathway when exposed to 125 uM taurolidine. In HMPOS
cells, with apparent mutant p53, p53 was down-regulated
suggesting cell death may occur through different pathways in this
cell line. Clone 4 and COS cells did not show any p53 expression at
any concentration of taurolidine tested (data not shown).
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Drug levels above 125 μM had little, if any, additional
benefit and cell death at these concentrations appeared
to occur by a mechanism other than apoptosis. This is
consistent with previously reported findings that showed
taurolidine promotes apoptosis at lower concentrations
and necrosis at higher concentrations [11].
The most commonly used chemotherapeutic agents for
OS in dogs are doxorubicin, carboplatin, and cisplatin
[30] although doxorubicin and carboplatin are currently
preferred because cisplatin is highly nephrotoxic in dogs.
Accordingly we sought to determine the potential for a
synergistic interaction when exposing cells to taurolidine
and doxorubicin or carboplatin. Only certain combinations
of taurolidine and doxorubicin or taurolidine and carbo-
platin achieved a surviving fraction (SF) of cells that was
different from that of each drug by itself (Figure 2A and B).
When the SFs were different, the interaction between the
drugs was synergistic. In the experiments with carboplatin
we chose to also test taurolidine at 100 μM to reflect
the concentration achieved in the serum of dogs (Seguin,
unpublished data). At that concentration, taurolidine alone
was so effective that in essence adding carboplatin could
not improve on those results (Figure 2B). Our drug com-
bination studies demonstrate taurolidine can be combined
to enhance the sensitivity of OS cells to doxorubicin or car-
boplatin in vitro. Optimal drug concentrations and incuba-
tion periods appeared cell line dependent and were not
fully elucidated here.
Once we learned that dogs are allergic to PVP, we
changed to taurolidine without PVP to better reflect the
potential clinical use of taurolidine in dogs. PVP is a sta-
bilizing agent for storage purposes. Our experiments
indicated that PVP alone did not have cytotoxic activity
against OS cells in vitro. It is possible that without PVP,
the taurolidine solution could lose its biologic activity.
However our results show that taurolidine retains its
cytotoxic activity in the absence of PVP.
We performed two independent assays of apoptosis that
show the cytotoxic effects of taurolidine at 125 μM pro-
ceeds through apoptotic mechanisms in canine OS cells.
Our results reveal that apoptosis begins within 4 hours
of taurolidine exposure and that response to taurolidine
depends on the cell line being tested. We speculated the
cell line-specific differences could be, in part, due to p53
functional status. Our results support this hypothesis
although definitive studies remain to be carried out in this
regard.Conclusion
Taurolidine is cytotoxic to canine OS in vitro and has
the potential to enhance the cytotoxicity of doxorubicin
or carboplatin in animals with OS. Preliminary clinicaltrials to test this hypothesis are currently underway in
our facility.
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